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Abstract
Human stem cells harbor significant potential for basic and clinical translational research as well as regenerative
medicine. Currently ~ 3000 adult and ~ 30 pluripotent stem cell-based, interventional clinical trials are ongoing
worldwide, and numbers are increasing continuously. Although stem cells are promising cell sources to treat a
wide range of human diseases, there are also concerns regarding potential risks associated with their clinical use,
including genomic instability and tumorigenesis concerns. Thus, a deeper understanding of the factors and
molecular mechanisms contributing to stem cell genome stability are a prerequisite to harnessing their therapeutic
potential for degenerative diseases. Chemical and physical factors are known to influence the stability of stem cell
genomes, together with random mutations and Copy Number Variants (CNVs) that accumulated in cultured human
stem cells. Here we review the activity of endogenous transposable elements (TEs) in human multipotent and
pluripotent stem cells, and the consequences of their mobility for genomic integrity and host gene expression. We
describe transcriptional and post-transcriptional mechanisms antagonizing the spread of TEs in the human genome,
and highlight those that are more prevalent in multipotent and pluripotent stem cells. Notably, TEs do not only
represent a source of mutations/CNVs in genomes, but are also often harnessed as tools to engineer the stem cell
genome; thus, we also describe and discuss the most widely applied transposon-based tools and highlight the
most relevant areas of their biomedical applications in stem cells. Taken together, this review will contribute to the
assessment of the risk that endogenous TE activity and the application of genetically engineered TEs constitute for
the biosafety of stem cells to be used for substitutive and regenerative cell therapies.
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Background
Origin of stem cell types
Regenerative medicine is a recent and emerging branch of
medical science, addressing functional restoration of spe-
cific tissues and/or organs of patients suffering from severe
injuries or chronic diseases in a condition where the organ-
ism’s own regenerative responses do not suffice [1]. Stem
cells are defined by their ability to regenerate multiple dif-
ferentiated cell types, while retaining the capacity to
self-replicate and self-renew. Those found in vivo have dif-
ferent origins and can be divided into three broad categories
accordingly: embryonic (ESCs), foetal (FSCs) and adult stem
cells (ASCs). Among the latter are hematopoietic stem cells
(HSCs) and mesenchymal stem cells (MSCs), which repre-
sent the most used stem cell types in current clinical trials.
ESCs are derived from the inner cell mass of human
blastocysts, have the potential for self-renewal, and are
considered pluripotent: they maintain the ability to dif-
ferentiate into cells and tissues from the three main
germ layers [2] and generate all the tissues found in an
organism. Human embryonic stem cells (hESCs)
emerged as a primary cell source for regenerative medi-
cine in recent years, to repair tissue and organ anomalies
that resulted from congenital defects, disease, age and
environment-associated effects. Similar characteristics
are associated with induced pluripotent stem cells
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(iPSCs), although these are generated in vitro by ectopic
expression of endogenous pluripotency factors which
epigenetically transform terminally differentiated cells
into ESC-like cells [3, 4].
FSCs, the second category of stem cells, are located in
foetal tissues and embryonic annexes and are multipo-
tent: they can differentiate into cell types from some, but
not all of the three main germ layers [5]. FSCs have been
subdivided into hematopoietic (blood, liver, bone mar-
row), mesenchymal (blood, liver, bone marrow, lung,
kidney and pancreas), endothelial (bone marrow, pla-
centa), epithelial (liver, pancreas) and neuronal stem
cells (neurons, glia and oligodendrocytes [6].
The third category, termed ASCs or progenitor cells,
comprises multipotent tissue-resident stem cells found
in fully developed tissues. They reside in niches that cre-
ate a special microenvironment for their replication and
self-renewal. Domiciled in most tissues of the human
body, discrete populations of ASCs generate cells to re-
place those that are lost through normal repair, disease,
or injury. ASCs are found throughout the lifetime of the
organism and were identified in tissues such as the um-
bilical cord, placenta, bone marrow, muscle, brain, fat
tissue, skin, gut, etc. ASCs are thought to act to repair
and regenerate tissues in which they reside, helping to
maintain tissue homeostasis.
Clinical application of adult and pluripotent stem cells
Adult stem cells such as HSCs, MSCs, and neural stem
cells (NSCs) are the most frequently used cell types in
interventional clinical trials (www.clinicaltrials.gov)
(Fig. 1a). HSCs are essential for the generation and
homeostasis of the blood system, and give rise to all
blood cell types, including lymphocytes, erythrocytes,
monocytes, granulocytes, and platelets [7]. Indeed, HSC
transplantation is the accepted therapy of choice for a
variety of malignant and non-malignant blood-related
diseases in children and adults. Initially developed as
rescue therapy for a patient with cancer after high doses
of chemotherapy and radiation, as well as the correction
of severe deficiencies in the hematopoietic system, it has
evolved into an adoptive immune therapy for malignan-
cies and autoimmune disorders [8]. Human MSCs are
multipotent stem cells with the capacity to differentiate
into the mesodermal lineage such as osteocytes, adipo-
cytes and chondrocytes, as well as some ectodermal
(neurocytes) and endodermal lineages (hepatocytes) [9].
MSCs have been isolated from various tissues including
bone marrow, adipose tissue, amniotic fluid, endomet-
rium, dental tissues, umbilical cord and Wharton’s jelly
[9]. MSCs have immunomodulatory features and se-
crete cytokines and immune receptors which regulate
the microenvironment in the host tissue [10]. Multili-
neage potential, immunomodulation and secretion of
anti-inflammatory molecules makes MSCs an effective
tool in the treatment of chronic diseases. Consequently,
there are several clinical trials harnessing their innate
characteristics or other in vitro observations in a series
of diseases (for a review see [11]). NSCs are a group of
ectodermal progenitor cells which can differentiate into
neural subtypes, such as neurons, astrocytes or oligo-
dendrocytes. Neural stem cell derivatives are used in a
number of clinical trial applications including treat-
ments of ALS and Parkinson’s Disease [12–14] and cur-
rently ongoing interventional clinical trials (Fig. 1a).
In contrast to MSCs and other types of tissue-specific
stem cells, pluripotent stem cells (PSCs) are derived either
from human pre-implantation embryos, giving rise to
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Fig. 1 Human stem cell-based clinical studies conducted worldwide
(Status: October 2018; www.clinicaltrials.gov). a Interventional clinical
trials (Phase I or phase I/II) applying adult stem cell types (mesenchymal
stem cells, MSCs; hematopoietic stem cells, HSCs; neuronal stem cells,
NSCs) or their differentiated derivatives, or embryonic stem cell (ESC)-or
induced pluripotent stem cell (iPSC)-derived differentiated cells. Numbers
in brackets indicate the number of individual trials based on the
respective stem cell type. b Interventional clinical trials and
observational studies that are currently ongoing or in preparation use
therapeutic derivatives of ESCs (blue lettering) or iPSCs (green lettering)
to treat ophthalmic, urological, blood, cardiac and genital diseases,
neurological disorders and cancers/neoplasms. Numbers in brackets
represent the number of clinical trials and/or observational studies
initiated to treat the respective disease or disorder
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to a primitive pluripotent state (hiPSCs). PSCs are immortal
and highly expandable in culture in vitro, and can be differ-
entiated to almost any cell type of the body. Their potential
for regenerative medicine is therefore unique and extraor-
dinary. Indeed, cellular products derived from hESCs are
now in clinical trials for cardiac and ophthalmic diseases
and neurological disorders, with some other applications
registered for clinical trial approval (Fig. 1b) [12–14]. Ini-
tially, hiPSCs have been used in one experimental proced-
ure in an autologous approach on an individual in Japan
with macular degeneration [16, 17]. In March 2017, the first
study was initiated involving 5 AMD (Age-related macular
degeneration) patients who received retina cells derived
from banked hiPSCs in an allogeneic approach [18]. To
date, 11 interventional clinical trials and 25 observational
studies are based on the application of iPSCs (Fig. 1). How-
ever, and despite these trials in the frontier of knowledge,
relatively little is known about undesired long-term effects
of such approaches.
The issue of genomic integrity
The promise for human disease treatment using differ-
entiated cells derived from multipotent ASCs and pluri-
potent stem cells, such as hESCs and hiPSCs, also
carries the threat of genomic instability of the cells to be
administered. Firstly, cultivation of multipotent and
pluripotent stem cells exposes the cells to selection pres-
sures that often result in the acquisition and manifest-
ation of genomic alterations, varying in size from point
mutations, through copy number changes in small
genomic elements (e.g. amplification of repetitive se-
quences and retroelement mobility), to large chromo-
somal aberrations, trisomies and monosomies [19–21].
Previous reviews reported several factors that contribute
to differences in genomic and epigenomic stabilities of
stem cells, including derivation source (embryonic vs.
somatic cells), derivation methods (direct isolation vs.
reprogramming), and culture conditions [22]. Much at-
tention has been drawn in recent years to the genomic
aberrations acquired by hESCs and hiPSCs, ranging from
point mutations to whole-chromosome trisomies [23–
30]. Similarly, human ASCs that are expanded in culture
were also shown to be prone to acquire chromosomal
aberrations [24]. Secondly, the treatment of many hu-
man diseases often involve genetic manipulation of stem
cells prior to transplantation, which may further
jeopardize their genomic stability. Overall, genomic ab-
errations can affect identity, differentiation capability
and tumorigenicity of stem cells, and should thus be
routinely evaluated for their proper use in basic research
and in clinical trials. In the promising era of stem cell re-
search and therapy, ensuring genomic stability of stem
cells and their derivatives remains one of the highest pri-
orities prior to clinical translation.
In this review, we focus on one specific source of gen-
omic instability in human therapeutically relevant stem
cells that has been mostly ignored by the stem cell com-
munity to date, namely the activity of endogenous
non-Long Terminal Repeat (non-LTR)-retrotransposons,
and the consequences for genomic integrity and host
gene expression. Non-LTR retrotransposons constitute
our center of attention because in contrast to most TEs
in our genome, a small fraction of this group of TEs is
currently active and mobilized in the human population
[31, 32]. We provide an overview of the impact of en-
dogenous TEs in pluripotent and adult stem cells, dis-
cuss new roles of TEs in regulating pluripotency, and
describe host defense systems counteracting TE activity
in stem cells. Furthermore, we address the application of
DNA-transposons to genetically engineer human stem
cells for medical applications. In order to fulfill the stan-
dards for safe clinical applications and evaluate the risk
for biosafety inflicted on therapeutically relevant cells by
TE activity, we propose that the extent of the activity of
potentially mutagenic TEs in pluripotent stem cells
needs to be elucidated, and perhaps used as an add-
itional quality control check point in the future.
Non–LTR retrotransposons are currently active in
the human genome
Retroelement families
More than 45% of the human genome is made of
TE-derived sequences, but only a specific subset of these
TEs that belongs to the group of retrotransposons is cur-
rently propagating in the human genome. Retrotranspo-
sons spread by a ‘copy-and-paste’ mechanism that
involves reverse transcription and insertion of an inter-
mediate RNA at a new site in the genome. They are clas-
sified in two different groups: LTR-retrotransposons,
which include human endogenous retroviruses (HERVs)
and are flanked by long terminal repeats harbouring
transcriptional regulatory domains, and non-LTR retro-
transposons that lack LTRs (Fig. 2). Among the 31 hu-
man endogenous retrovirus subfamilies covering 8% of
the human genome, replication-competent HERVs have
not been described to date, although their existence can-
not be ruled out [33, 34]. The only TEs that are cur-
rently verifiably mobilized in the human genome are
members of the group of non-LTR retrotransposons
(Fig. 2). They comprise two main types of elements: i)
autonomous Long interspersed class 1 elements
(LINE-1s or L1s), and ii) non-autonomous short inter-
spersed elements (SINEs) such as Alu and SVA
(SINE-VNTR [variable number of tandem repeats] -Alu
elements) elements. In humans, > 500,000 L1 copies oc-
cupy ~ 17% of the haploid genome [35]. A functional,
full-length L1 is 6 kb in length and initiates transcription
using an internal sense-promoter located within its 5′
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untranslated region (UTR) [36–38] (Fig. 2). In functional
L1s the sense promoter drives expression of two pro-
teins, named ORF1p and ORF2p, that catalyze L1 retro-
transposition in cis [39]. ORF1p is a 40 kDa RNA
binding protein with nucleic acid chaperone activity,
while ORF2p is a 150 kDa protein that contains reverse
transcriptase (RT) and endonuclease activities (reviewed
in [32]). Both proteins are strictly required for retrotran-
sposition [40] by a process termed Target-Primed Re-
verse Transcription (TPRT; [41, 42]). A conserved
antisense-promoter in the L1 5’UTR [36, 37] drives ex-
pression of the trans-acting polypeptide ORF0, that can
stimulate L1 mobilization [43]. Although the RT activity
of human L1 was shown to be highly processive [44],
most de novo L1 insertions are rendered immobile by 5′
truncation. These truncations together with internal mu-
tations accumulated over time, have resulted in only
80–100 retrotransposition-competent or functional L1s
per individual human genome [45–47]. Of these, fewer
than 10 mobilize efficiently when tested in vitro: they
are termed ‘hot’ L1s and responsible for the bulk of ret-
rotransposition in the human population [45, 47–50].
The vast majority of hot L1s belong to the youngest sub-
family, termed L1Hs (for Homo sapiens-specific, also
known as L1-Ta, for transcribed-active) [45, 47, 51]. L1
subfamilies can be distinguished by nucleotide substitu-
tions that are shared by all members of a specific sub-
family. Five subfamilies are thought to have amplified in
hominoid primates within the past 25 myrs, named
L1PA1 to L1PA5. Functional L1 s are also responsible
for the mobilization of Alu and SVA elements which
lack protein-coding capacity [52–55]. Indeed, L1 activity
in trans can act at low frequency on any cellular
polyadenylated mRNA, resulting in the generation of
processed pseudogenes [56, 57]. Members of the
primate-specific Alu family are approximately 300-bp
long, have a dimeric structure, and are transcribed by
RNA polymerase III (reviewed in [58, 59]) (Fig. 2). The
Fig. 2 Retrotransposons in the human genome. Currently, only LINE-1 (L1), Alu and SVA elements are verifiably still mobilized in humans. A full
length HERV-K provirus is ~ 9.5 kb long, codes for group-specific antigen (Gag), protease (Pro), polymerase (Pol) and envelope (Env) proteins and
is flanked by ~ 1-kb long terminal repeats (LTRs) with the 5’LTR including the HERV-K promoter. A functional full length L1 element is ~ 6 kb in
length, harbours three open reading frames (ORF0, ORF1 and ORF2) at which ORF1 and ORF2 are separated by a 63-bp noncoding spacer region.
The 5′ untranslated region (5’UTR) harbours both sense and antisense promoter. Alu elements comprise ~ 280-300 bp, are composed of two
7SL-RNA derived monomers separated by an A-rich connector (A5TACA6), contain an internal A and B box promoter, and end in a poly A tail (An).
SVA elements are ~ 0.7–4 kb long, consist of a 5′ hexamer repeat that can be variable in length ((CCCTCT)n), two Alu fragments in antisense
orientation, a GC-rich variable number of tandem repeats (VNTR) region, a SINE-R sequence derived from an HERV-K10 element and a poly A tail
following a polyadenylation signal. The length of an intact SVA can vary depending on the number of repeats present in the hexamer and VNTR
domains. L1, Alu and SVA insertions are characterized by the hallmarks of L1-mediated retrotransposition such as flanking variable target site
duplications (TSDs), polyA tails at their 3′ ends (An) and insertion at the consensus target sequence 5′-TTTT/AA-3′. 3’UTR, 3′ untranslated region
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family of Alu elements is, with > 1 million copies, the
most abundant TE in our genome [35], and represents
the currently most active group of retrotransposons in
humans with ~ one thousand mobilization-competent
copies per genome. The SVAs are hominid-specific com-
posite non-coding retroelements, with an average length
of ~ 2 kb, and represent the youngest family of active hu-
man TEs (Fig. 2). There are roughly 2700 SVA copies
per human genome, most of which are full-length and
about 20–50 of which may be active [60–67].
In sum, all above listed mobilization-competent non-LTR
retrotransposons may collectively account for thousands of
somatic insertions [68]. It was calculated that up to 5% of
newborns harbour a new retrotransposition event, and >
120 known human disease-causing insertions of L1 s, Alus
and SVAs have been identified to date [69–73].
L1-mediated insertions have sporadically resulted in a wide
number of human genetic disorders, including hemophilia
A (L1), cystic fibrosis (Alu) [74] and X-linked dystonia-par-
kinsonism (SVA) to cite a few reviewed in [71]. Altered ex-
pression of TEs and animation of genomic L1 sequences
also appear to be hallmarks of cancer, and can be respon-
sible for driving mutations in tumorigenesis [75, 76]. In-
deed, the random mobilization of L1 in our genome
implies that virtually any disorder can be generated by the
mutagenic activity of non-LTR retrotransposons, and
L1-mediated retrotransposition events occur approximately
once in every 250 pathogenic human mutations [77].
TE insertions can affect host gene expression by various
mechanisms and impact stem cell development
When expressed, TEs can affect developmental processes
either by their encoded gene products, which could in-
fluence phenotype and/or function of the host cell, or
through their genomic de novo insertion, that could re-
sult in genetic changes in the host genome. L1-mediated
retrotransposition events can be associated with the in-
duction of local genomic instability, including DNA de-
letions at the insertion site, 3′- or 5′-transductions, and
non-allelic homologous recombination (reviewed in [32,
78]). Additionally, new retrotransposon insertions into
genes can act as insertional mutagens, alter gene expres-
sion and interfere with host gene function [79].
Although fewer than 1 of 10,000 TEs is still capable of
mobilization [71], a far greater proportion can influence
gene expression in cis and in trans (reviewed in [80]).
This is because TEs, such as ERVs, L1 and SVA ele-
ments, contain transcription factor binding sites that
promote transcription by RNA polymerase II or, in the
case of Alu elements, by RNA polymerase III. Therefore,
the promoter(s) of resident and new TE(s) that inte-
grated into or close to host genes, can alter gene expres-
sion, and even lead to the appearance of novel
transcripts that encompass part of the coding region.
For instance, because transcripts of several host genes in
iPSCs originate from a nearby L1 antisense promoter,
the most abundant transcript isoforms expressed contain
L1 ORF0 sequences whereas for other genes, these iso-
forms contribute only little to the bulk transcripts. Inter-
estingly, ORF0 transcript levels were dramatically
downregulated in the source fibroblasts relative to their
derived iPSCs [43]. De novo genic insertions can also in-
duce premature termination of transcription by introdu-
cing TE-derived polyadenylation signals [81], and
sporadically result in the exonization of TEs. Exonized
TEs can expand the mammalian transcriptome and
proteome, but can also be used to fine-tune gene regula-
tion [82]. Indeed, nucleotide sequences of several classes
of TEs have been found inserted within mammalian
RNAs [82–84] raising the possibility that they affect
gene regulation and function by providing or interfering
with regulatory elements in those RNAs. While the de-
crease in host gene RNA expression due to inadequate
transcript elongation after L1 insertion in an intron of a
transcribed gene was originally attributed to the A/T
richness of the L1 sequence [85], it was suggested re-
cently that transcriptional attenuation of host gene ex-
pression could be a consequence of epigenetic silencing
mediated by the human silencing hub (HUSH) complex
[86]. TE insertions can also introduce TE-derived splice
acceptor or donor sites that alter splicing, and thereby
generate non-functional or nonsense transcripts [87] or
can be incorporated into mRNAs and thus introduce
frameshifts or premature termination codons. It has also
been shown recently that spliced L1 mRNAs are also
used as templates generating spliced integrated retro-
transposed elements (SpIREs) which lack part of the
5’UTR and, consequently, lack some of the regulatory
sequences [88]. L1-encoded proteins can sporadically
generate processed pseudogenes [39, 56], and thereby
affect the stem cell transcriptome and proteome. Finally,
ongoing L1 retrotransposition itself can copy regulatory
sequences such as promoter and enhancer regions and/
or protein coding regions and introduce them into new
sites in the host genome by a mechanism termed “exon
shuffling” [89]. Exon shuffling occurs when an L1 insert
resides within a gene, L1 transcription bypasses the in-
herent weak L1 polyadenylation signal, and transcribes
downstream exons generating a chimeric RNA, which
could then retrotranspose to a new genomic location. It
is estimated that ~ 15–20% of the L1Ta subfamily mem-
bers in the human genome contain 3′-transduced se-
quences. Such L1-mediated 3′ transductions are
responsible for as much as 1% of the human genome
[90, 91], and this process has probably increased the rep-
ertoire of the human proteome. In summary, there are
multiple manners in which TE insertions can impact the
functioning and regulation of the human genome.
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Activity of non-LTR retrotransposons in human
pluripotent stem cells
Primary milieu for the evolutionary struggle between TEs
and the host genome are pluripotent cells of the early
mammalian embryo and germ cells
To ensure their evolutionary success, TEs need to
mobilize in germ cells and/ or during early development,
before germline partitioning, to guarantee transmission of
new retrotransposition events to the next generation. A
genome-wide epigenetic switch in the early mammalian
embryo, characterized by global DNA demethylation, is
necessary to activate the programme of embryonic devel-
opment. This ‘epigenomic reset’ is thought to provide a
window of opportunity for retrotransposons to mobilize
and create heritable insertions [92], as L1 expression is
also controlled by DNA methylation [93]. Consistently,
previous studies have shown that i) L1 mRNAs are present
in human immature diploid oocytes from in vitro
fertilization donors [94], ii) both L1-encoded proteins,
ORF1p and ORF2p, are expressed in prespermatogonia of
fetal testes and in germ cells of adult testes [95], and iii)
hESCs overexpress a combination of potentially functional
full-length L1 and core Alu elements as well as
non-functional L1 and Alu RNAs (Fig. 3) [79, 96–100].
The observed L1 expression levels in these pluripotent
stem cells inversely correlate with both their low global
DNA methylation levels, and their levels of L1 promoter
methylation [97, 101, 102]. It has been reported that only
a specific subset of L1 retrotransposons, likely under the
combined influence of activators or repressors and local
chromatin constraints, is active at any given period of
early embryogenic development type [67, 96, 103, 104].
While expression of members of the youngest L1 lineages,
L1Hs and L1PA2, is highest in hESCs, expression of a sub-
set of L1 lineages, primarily L1PA3, L1PA4, L1PA5 and
L1PA6, which were predicted to have entered the ances-
tral genome between 26.8 and 7.6 million years ago, is re-
duced [98]. Thus, these data demonstrated that RNAs
from active and “hot” L1 s are expressed in hESCs and
hiPSCs. Using an engineered L1 retrotransposition re-
porter assay in cultured cells [40], it was demonstrated
that the cellular environment of human and murine ESCs
support L1 retrotransposition (Fig. 3), and that L1 de novo
insertions in cultivated hESCs can occur into genes and
lead to small deletions of genomic DNA at the target site
[97, 105, 106]. In agreement with these data demonstrat-
ing that host factors essential for retrotransposition of
functional L1 mRNAs are present in hESCs, it was verified
that endogenous AluYa5 elements are trans-mobilized in
cultured hiPSCs [79].
Fig. 3 Schematic of relative endogenous L1 expression levels and engineered retrotransposition frequencies in human ESCs and adult stem cells
derived from mesoderm and ectoderm. Relative L1 mRNA and L1 ORF1p expression levels, and relative engineered L1 retrotransposition frequencies
supported by the respective cell type are illustrated: ++++, very high; +++, high; ++, moderate; +/−, barely detectable and therefore very low. HSC,
Hematopoietic Stem Cells; MSC, Mesenchymal Stem Cells; ESC, Embryonic Stem Cells; NPC, Neural Progenitor Cells; KER, Human Foreskin Keratinocytes
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Somatic and heritable L1-mediated retrotransposition in
pluripotent stem cells during early development
Studies of transgenic mouse models established to inves-
tigate engineered L1 retrotransposition in vivo, and,
more recently, the sequencing of mouse pedigrees, con-
firmed that the majority of heritable de novo retrotran-
sposition events in mice occur in preimplantation
embryos, and indicate that embryonic cells are likely to
be the natural habitat for L1-mediated retrotransposition
[107–113]). Notably, such L1 mobilization in pluripotent
cells of pre-implantation embryos could result in the
new insertion being a mosaic within somatic and germ-
line cells in adult mice. Although it was reported that L1
transcript levels peak after fertilization at the 2-cell-stage
and decrease from the 2- to the 8-cell stages in mice
[114], it remains unclear at which time point after
fertilization L1-retrotransposition is initiated. Endogen-
ous L1 elements were shown to be active in mouse early
primordial germ cells, before the PIWI/piRNA retro-
transposon defense pathway is activated in male embry-
onic gonads [113, 115].
By contrast, we currently know relatively little about TE
expression and timing of retrotransposition in humans.
An example that unambiguously proves that endogenous
L1 mobilization can occur early in human embryogenesis
was reported by van den Hurk and colleagues: they char-
acterized a mutagenic L1 insertion resulting in choroider-
emia, a rare recessive X-linked eye disorder, in an affected
male patient whose mother was a somatic and germline
mosaic for the pathogenic L1 insertion [116]. Due to a 3′
transduction carried by the mutagenic L1 insertion, the
authors were able to identify the specific donor L1 elem-
ent and verify that it was retrotransposition-competent
[116, 117]. Taken together, data strongly suggest that, in
humans, new heritable L1 and Alu insertions can likely ac-
cumulate during early embryogenesis, and to some extent
in germ cells [97, 107, 110]. Retrotransposition events me-
diated by L1 were estimated to occur, at a minimum, in 1
of 20 meioses for Alu, 1 of 20 to 200 meioses for L1, and 1
of 900 meioses for SVA [118]. Clearly, future studies
should determine the timing of L1 retrotransposition dur-
ing embryogenesis and a rate of retrotransposition in
modern humans.
Very recently, studies in mice provided evidence that
the observed transcriptional L1 activation may have a role
in mouse ESCs and pre-implantation embryos. Activation
of L1 transcription after fertilization regulates global chro-
matin accessibility at the beginning of development, and
therefore could be important for normal embryonic devel-
opment [119]. Also, the L1 RNA seems to act as a nuclear
scaffold to repress the transcriptional program specific to
the 2-cell embryo and, consequently, the L1 transcript
could be required to exit from the 2-cell stage [120].
These data suggest that L1-encoded RNAs and proteins
have additional roles in embryonic development. These
findings seem paradoxical, as despite the mutagenic po-
tential of L1 during embryogenesis, they suggest that L1
activity could be required for proper embryonic develop-
ment and even to maintain ESC identity.
TE activity as parameter to define the naïve pluripotent
state in hESCs
Mouse ESCs and iPSCs were proposed to represent a
naïve state of pluripotency corresponding to the inner cell
mass, whereas hESCs/iPSCs correspond to a more ad-
vanced, or ‘primed’, state of pluripotency found in the
postimplantation epiblast [121]. Indeed, it has been chal-
lenging to define the naïve state of pluripotency in hESCs,
particularly in view of the expanding number of protocols
for deriving putative naïve human cells [122, 123]. Putative
naïve human cultured cells were examined according to
their resemblance to human pluripotent cells in vivo.
Three comparative parameters for evaluating the naïve
state of human pluripotent stem cells were established: (1)
the expression profile of TEs based on single-cell
RNA-seq data [124], (2) the DNA methylation landscape
of human preimplantation development [125], and (3) the
chromosome X inactivation status of female human ESCs
[126, 127]. Comprehensive examination of the “transpo-
scriptome” was found to offer a more sensitive measure of
the correspondence between pluripotent stem cells and
the early human embryo than gene expression profiling
[128]. Constituting a unique model system to dissect
mechanisms of early human development, naïve hESCs
provide an excellent cellular model to interrogate the
function of transposable elements that become activated
during early human development [128].
Cultured human pluripotent stem cells support
expression and mobilization of endogenous TEs
Human iPSCs are currently successfully applied for dis-
ease modeling, the study of cell development and func-
tion, and for in vitro screening of drug candidates on
healthy and diseased cells; thus, cellular products de-
rived from hiPSCs hold substantial promise for substitu-
tive and regenerative, autologous and allogenic cell
therapies. Unlike hESCs, hiPSCs are a potential source
of autologous cells compatible with the immune system
of transplant recipients [129]. hiPSCs also circumvent
ethical issues associated with the use of human embryos
to derivate hESCs [129]. However, genetic and epigenetic
aberrations that occur during reprogramming and in
vitro expansion [25–28, 79, 130] may hinder the use of
hiPSCs in regenerative medicine because they could
affect their identity and differentiation capability, and
could elevate the risk of tumorigenesis upon implant-
ation [131]. Thus, identifying the full spectrum of aber-
rant mutational processes accumulated in hiPSCs, and
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their functional consequences, is of paramount signifi-
cance. A direct consequence of reprogramming, due to
genomewide epigenomic changes [130], is the activation
of full-length L1 mRNA expression; indeed, L1-ORF1p
and L1 RNA transcript levels are upregulated by up to
four orders of magnitude compared to their respective
parental cells [79, 100, 132, 133]. To investigate if hiPSCs
provide the environment for L1 retrotransposition, Wis-
sing and colleagues exploited an in vitro L1 retrotranspo-
sition assay, and detected similar levels of L1-engineered
retrotransposition as those previously reported in hESCs
[97, 100]. These data demonstrated that the cellular milieu
of both hESCs and hiPSCs contains the host factors re-
quired for L1 retrotransposition. In order to clarify if the
transcriptional activation of endogenous L1 elements in
hiPSCs leads to L1-mediated mobilization, targeted se-
quencing was performed on cultured hESC and hiPSC
lines, followed by PCR validation of candidate de novo L1,
Alu and SVA insertions in multiple laboratories [79]. Not-
ably, the sequencing of a small number of lines revealed
ongoing L1, Alu and SVA retrotransposition in hiPSCs;
Similarly, one Alu de novo insertion was found to have oc-
curred during the cultivation of the hESC line H9, which
was the only hESC line analyzed in this study [79]. Thus,
these studies confirmed that hESCs and hiPSCs are a nat-
ural habitat for L1-mediated retrotransposition, consistent
with heritable retrotransposition during early human em-
bryogenesis. However, the currently available datasets on
L1 mobilization in hiPSCs vs hESCs are not sufficient to
allow conclusions on the frequency of L1-mediated retro-
transposition events in individual hESCs or hiPSCs.
Remarkably, an earlier whole-genome sequencing (WGS)-
based study in mouse ESCs failed to detect endogenous
L1 retrotransposition [134]. Lack of retrotransposition in
mESCs when compared to hESCs/hiPSCs might reflect
distinctly different properties of human primed [79] and
mouse naïve [134] pluripotency states; or the limitations
of the method employed for detecting de novo retrotran-
sposition events, namely genome-wide DNA sequencing
with [79] or without [134] a previous retrotransposon en-
richment step. Overall, these data might suggest that the
genome of mESCs would be more stable than hESCs/
hiPSCs, although several studies have presented compel-
ling evidence demonstrating ongoing (and heritable) L1
retrotransposition during early mouse embryogenesis
[107, 113]. Thus, it is also possible that cultured mESCs
fail to recapitulate this aspect of mouse early embryonic
biology, and additional studies are required to solve this
contradiction.
Occurrence and structures of de novo retrotransposition
events in cultured hESCs and hiPSCs
An intriguing aspect of L1 retrotransposition studies in
hESCs/hiPSCs is that most validated insertions are
full-length. In hiPSCs, 57–66% of all validated endogen-
ous and engineered L1 de novo retrotransposition events
were full-length [79, 100]. Another report found seven
potential de novo L1 insertions in two hiPSC lines using
targeted L1 sequencing, but could not PCR-validate or
fully characterize the genomic integration sites of these
events [133]. The success in the identification of L1
mobilization events depends on multiple factors such as
heterogeneity of the investigated cell population, and
methodological factors such as stem cell culture condi-
tions, population bottlenecks in cultured cells,
high-throughput sequencing method used, bioinformatic
parameters, and how candidate L1 insertions are vali-
dated, which can affect the results decisively. For ex-
ample, a recent study applied WGS to nine hiPSC lines
[135] and did not identify any de novo retrotransposon
insertions, and far fewer mutations overall when com-
pared to earlier studies [25, 26]. While an early report in
hESCs validated a small number of engineered but
5′-truncated L1 insertions [97], additional insertion
characterization in hESCs has recently revealed that >
70% of them are full-length (Cano and Garcia-Perez,
personal communication). The finding that 66–75% of
engineered L1 retrotranposition events in hESCs and
hiPSCs are full-length is in stark contrast to the situation
in cancer cell lines, where only ~ 5% of engineered L1 de
novo insertions represent full-length elements [136].
While this discrepancy warrants additional research, it is
tempting to speculate that due to L1 overexpression,
host factors involved in 5′ truncation might be titrated/
sequestered in hESCs/hiPSCs allowing a higher rate of
full-length insertions in these cells. Notably, other fea-
tures of de novo L1 insertions events do not differ sig-
nificantly between cancer cells and hESCs/hiPSCs; For
example, ~ 50% of all validated L1 retrotransposition
events in both cell types occurred into introns of host
genes [79, 100, 136]. Similar to transformed cells, in-
tronic L1 insertions into hiPSCs can interfere with the
transcription of the affected host gene [79].
Epigenomic reprogramming causes a constant
derepression of endogenous TEs
Despite the unknown aspects of L1 biology in ESCs, avail-
able data indicate that reprogramming elicits a dynamic
but consistent derepression of endogenous L1 s, and that
they experience a relaxation of host genome control in
pluripotent stem cells obtained from embryonic tissues
[111, 128, 132, 137, 138]. A recent study examining tran-
scriptional control of endogenous retroelements during
the reprogramming of human hematopoietic stem cells
from cord blood and primary hepatocytes into hiPSCs and
subsequent cultivation uncovered a marked transcrip-
tional upregulation of active SVA_A and L1Hs
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retrotransposons, but also of currently inactive HERV-K,
HERV-H and HERV-W elements [132]. A sharp increase
of L1 and SVA transcription was observed several days
after transduction with reprogramming vectors, and both
RNAs remained highly expressed upon culturing hiPSCs
[132]. While there was only little heterogeneity in L1 ex-
pression levels between tested hESC lines, considerable
heterogeneity between hiPSC clones was observed [132].
Comparison of expression levels of individual endogenous
retroelements between hiPSC clones derived from a single
donor and issued from the same reprogramming experi-
ment uncovered striking differences, notably for HERV-H,
HERV-K and L1Hs. Thus, these data suggest that the gen-
ome wide epigenomic reprogramming might not occur to
the same extent in all reprogrammed cells, and that hESCs
might represent a more realistic model to study human
early embryogenesis processes. It was hypothesized that
transcriptionally activated functional L1Hs elements,
whose antisense promoters can affect the expression of
neighbouring genes [139], have a similar effect during or
after reprogramming of hiPSCs [132]. The interference of
cis- and trans-acting transcriptional regulatory elements
of preexisting or de novo TE insertions with the transcrip-
tion of TE-close genes may result in phenotypic anomalies
difficult to detect through conventional assays, such as
blockade of differentiation to particular lineages, predis-
position to oncogenic changes, aberrant release of bio-
active molecules, altered immunogenicity or ectopic
activation of disease-related genes in iPSCs or their pro-
geny [67, 132]. In hiPSCs, unsteady production of tran-
scripts from TE-integrants normally silenced in ESCs and
secondary activation of neighbouring genes was noted
[67]. This phenomenon could contribute to the ineffi-
ciency of reprogramming by stochastically activated genes
that affect the path to pluripotency [140]. Transcriptional
perturbation of TE-close genes may also plague iPSCs and
their progeny with phenotypic anomalies [141]. These
findings argue for an in-depth survey of the genomic,
transcriptional, and epigenetic state of the repetitive gen-
ome of iPSC clones, that are to be used for basic research
or clinical applications. In these studies, bona fide estab-
lished hESC lines could offer an excellent reference to de-
tect harmful changes in hiPSCs that might limit their
applications. Indeed, and while the use of hESCs on re-
generative medicine is clearly limited, hESCs have become
an excellent benchmark to establish clinically safer human
pluripotent embryonic stem cell-like cells.
Activity of endogenous non-LTR retrotransposons
in adult stem cells
Breaking the dogma – TE activity in adult stem cells of the
brain
TEs are the prototype of “selfish DNA”, whose only pur-
pose is to generate more copies of themselves. Thus, it
was assumed for a long time that most TE activity in
mammals might occur only in cellular niches that trans-
mit genetic information to the next generation, as this
would ensure the evolutionary success of TEs. Although
pioneer work by Barbara McClintock discovered TEs in
somatic tissues of corn [142], the lack of TE activity in the
mammalian soma has been a long-standing dogma. How-
ever, this “dogma” was recently challenged with the de-
scription of TE activity in mammalian healthy somatic
cells, specifically in adult stem cells of the brain. The first
evidence for ongoing mobility of L1 s in adult stem cells
was obtained from neural precursor cells (NPCs) derived
from rat hippocampus neural stem cells [112]. It was dem-
onstrated that rodent NPCs can support elevated levels of
retrotransposition using engineered human L1 reporter el-
ements. By applying a transgenic mouse model it was
demonstrated that L1 s generate genomic somatic mosai-
cism during brain development and in adult mice. Con-
sistently, human NPCs isolated from fetal brain or derived
from hESCs were shown to express moderate levels of L1
RNA and L1-ORF1p (Fig. 3), and to significantly support
elevated levels of engineered L1 retrotransposition in vitro
[143]. These and previous studies in mice (i.e., [112]) rep-
resented a major breakthrough in the TE field, because it
was demonstrated for the first time that the endogenous
L1 copy number is increased in several regions of the hu-
man brain (including hippocampus) when compared to
other human somatic tissues [143, 144]. More recently,
the use of an adenoviral/L1 hybrid vector [145] has
allowed demonstrating L1 retrotransposition in
non-dividing mature neuronal cells, differentiated from
hESCs [99] (Fig. 3). While L1 s are usually repressed in
somatic tissues, the mechanism responsible for L1 activa-
tion in neuronal progenitor cells has been studied (for re-
view see [146, 147]). While the L1 promoter whose
activity is known to be regulated by CpG methylation [93,
148], and is hypermethylated in mature neurons, it is less
methylated than in fibroblasts [143] and these data sug-
gest that additional factors beside DNA methylation might
allow L1 to be expressed in neurons. The most accepted
current model for the regulation of L1 expression and ret-
rotransposition in neurons and NPCs involves the activity
of Sox2 and WNT3A in combination with DNA methyla-
tion. Briefly, Sox2, a negative regulator of neuronal differ-
entiation, is suggested to interact with the L1 promoter
and repress L1 expression in rodent and human neural
stem cells [112, 143]. Methyl-CpG-binding protein 2
(MeCP2) has been demonstrated to associate with the
L1 promoter in a methylation-dependent manner, and
to repress L1 expression in neural stem cells [149,
150]. Upon differentiation, Sox2 is downregulated, the
promoter of L1 is mildly demethylated and thereby
decreases binding of MeCP2 and increases L1 expres-
sion. At the same time, activation of WNT3A could
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stimulate L1 expression through the canonical Wnt
pathway [151].
Somatic L1 retrotransposition events accumulate during
various developmental steps
Above studies mostly used engineered L1 reporter con-
structs, although more recently sequencing-based ap-
proaches have been used to demonstrate ongoing
endogenous L1 retrotransposition in the human brain,
not only in NPCs but also in neurons [144, 152–154].
Several high-throughput sequencing methods for the de-
tection of endogenous retrotransposition events have
been recently developed and applied to brain-derived
samples (reviewed in [155]). Retrotransposon capture se-
quencing (RC-seq, [156]), and L1-seq [72] are two of the
methods used to demonstrate L1 retrotransposition in
neuronal cells isolated from cerebral cortex, caudate nu-
cleus and hippocampus. Although these studies have re-
ported significant variability in the inferred rate of L1
mobilization in the brain [144, 152–154, 157], the main
conclusion from these studies is that somatic L1 retro-
transposition events are accumulated during a variety of
neural development stages, including early progenitor
cells and mature neuronal cells. In summary, and while
current estimates of L1 retrotransposition rates in neu-
rons range from 0.04–0.6 to 13.7 L1 insertions per cell
(see [111, 146, 157]), it is clear now that our brain is
composed of a mosaic of genomes.
L1 retrotransposition occurs at very low level in the
majority of tested adult stem cell types
Is L1 active in other somatic tissues besides the brain, or
can all adult somatic stem cell types of the human body
support L1 retrotransposition? In order to address this
question, Macia and colleagues compared L1 expression
and engineered L1 retrotransposition among various hu-
man cell types using isogenic cells [99]. To this end, the
differentiation capability of hESCs was exploited to pro-
duce relatively pure populations of adult stem cells, which
were then used to study L1 expression and retrotransposi-
tion. Notably, this approach allowed comparing different
cell types that contain the same genetic background. Thus,
L1 expression and retrotransposition was analyzed in kera-
tinocytes (KERs, considered multipotent embryonic
progenitor cells generating epidermal barrier, hair and
nails), NPCs, fully differentiated neurons, MSCs and HSCs
(Fig. 3). This allowed comparing NPCs and neurons to an-
other ectoderm-derived cell type (KERs) and to multipo-
tent stem cell types derived from mesoderm (MSCs and
HSCs). Remarkably, data revealed that all cell types tested
express endogenous L1-mRNAs and encoded L1-ORF1p,
although there were significant differences in their expres-
sion levels (Fig. 3): L1-RNAs and L1-ORF1p were
expressed at similar low levels in all cell types but NPCs,
which expressed moderate levels of gene products as re-
vealed by RT-qPCR, immunoblot analysis and confocal mi-
croscopy [99]. Consistently, the absence of detectable
full-length L1 transcripts from human bone marrow-de-
rived MSCs was demonstrated [158]. Analysis of the
DNA-methylation status of L1 promoters in the various
differentiated cell types tested uncovered an inverse cor-
relation with L1 expression levels [99], which is consistent
with the hypothesis that DNA methylation is a major
mechanism to inhibit L1 retrotransposition in somatic
cells [159].
To investigate whether KERs, HFFs, neurons and multi-
potent NPCs, MSCs and HSCs support L1 retrotransposi-
tion, Macia and colleagues took advantage of a hybrid
adenovirus-based L1 vector that was specifically designed
to conduct experiments in non-dividing cells [160]. Con-
sistent with L1 expression data, L1 retrotransposition in all
cell types tested, was extremely low, except for NPCs (Fig.
3). However, this study confirmed elevated retrotransposi-
tion levels in NPCs, and demonstrated that non-dividing
mature neurons support L1 retrotransposition using engi-
neered L1 reporter elements in vitro. Thus, this data sug-
gests that L1 activity is not a generic property of all
somatic stem cell types of the human body. Intriguingly, a
recent report using transgenic mice carrying a human
engineered L1 reporter element suggests that ionizing ra-
diation does increase L1 expression in mouse HSCs, and
that these cells might express higher levels of L1 RNAs
than human HSCs [161]. Low levels of L1 retrotransposi-
tion observed in non-irradiated HSCs were also increased
upon irradiation [161]. However, it could not be ruled out
that some or most of the L1 retrotransposition events had
accumulated already during embryonic development [161].
The above studies suggest that, among the cell types an-
alyzed, L1 retrotransposition in adult multipotent stem
cells occurs at a very low level, with the exception of NPCs
(Fig. 3). These data also indicate that, even at low levels,
L1 activity in multipotent stem cells would result in new
L1 insertions carried by the derived specific tissues. Con-
sistently, several putative somatic L1 insertions have been
identified in healthy tissues, including liver [162], stomach
[163] and esophagus [164]. Although in this report, one
de novo insertion has been validated in tissues of colon
[163] and esophagus [164], respectively, additional re-
search is required to investigate to what extent endogen-
ous L1 mobilization occurs in healthy adult tissues or at
any earlier developmental stage. Considering that (just as
neuronal cells) the gastrointestinal tract is derived from
endoderm, extending L1 mobilization analyses to adult
stem cells derived from this germ layer may clarify if the
capability to support L1 retrotransposition is restricted to
NPCs or also applies to endodermal stem cell populations.
It was shown recently that heritable L1 insertions occur
not only in pluripotent embryonic cells, but also in early
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primordial germ cells (PGCs), at least in mice [113]. In
humans, PGCs represent the primary undifferentiated
stem cell type that differentiates towards gametes (sperm-
atozoa and oocytes). Due to the therapeutic potential of
PGCs for the treatment of infertility [165], the impact of
L1 activity in those cells should be given due regard. In
summary, among the adult stem cell types tested to date,
somatic L1 retrotransposition is restricted to NPCs and
PGCs, and does not seem to be a generic property of mul-
tipotent adult stem cells.
Regulation of TE activity in pluripotent stem cells
The human host is in a constant battle with TEs such as
L1 to prevent their amplification and overreaching activ-
ity, because functional, active L1 elements carry substan-
tial mutagenic potential. Somatic L1-mediated
retrotransposition in somatic cells, such as stem cells,
has also been linked to disease, especially in the context
of cancer [75, 76, 162, 166]. Mobility restriction of these
elements is therefore critical to maintain genome stabil-
ity, especially during germline establishment and early
embryogenesis, as new TE insertions in these cells can
potentially be transmitted to the next generation [167].
During the first few days of embryogenesis, most TEs
are targeted by silencing mechanisms and kept under con-
trol during early embryogenesis by epigenetic silencing
and post-transcriptional regulation of L1 mRNAs [99, 168,
169]. Epigenetic silencing of TE expression is mediated by
1) Krüppel-associated box domain-containing zinc finger
proteins (KRAB-ZFPs), mediators of heterochromatic for-
mation [98] 2) cytosine methylation, a process governed
by the action of DNA methyltransferase-3 like protein in
germ cells [93], and 3) ten-eleven translocation (TET)
family proteins [170]. TEs are recognized by
sequence-specific proteins- or RNA-based repressors, with
subsequent recruitment of heterochromatin-inducing
complexes [171]. Histone methylation, histone deacetyla-
tion, and DNA methylation control TE expression and re-
press their cis-acting transcriptional components, which
would otherwise activate neighboring genes via promoter
or enhancer effects [172–178]. Histone repressive marks
play a major role in this process, and trimethylation of his-
tone 3 at lysine 9 (H3K9me3) is a modification found in a
wide variety of TEs, including ERVs, LINEs, SINEs, and
SVAs in hESCs [98, 179–184]. Excellent reviews have been
published recently on how the host controls the activity of
active TEs [67, 110, 155]. In the following section, we will
address those host-encoded mechanisms that were re-
ported to interfere with the retrotransposition cycle specif-
ically in pluripotent stem cells.
Restriction of TE transcription
KRAB-ZFPs are the largest family of transcriptional reg-
ulators in higher vertebrates [185] and play a major role
in the early embryonic control of vertebrate TE expres-
sion, including ERV, LINE, SINE and SVA elements [98,
178, 184]. Harbouring an N-terminal KRAB domain and
a C-terminal array of DNA-binding zinc fingers, they
mediate silencing by recruiting the cofactor
KRAB-associated protein 1 (KAP1, also known as
TRIM28), which acts as a docking protein for proteins
with heterochromatin-forming activities, including the
H3K9 methyltransferase SETDB1 [178, 186]. The
KRAB/KAP1 system represses transcription of endogen-
ous retroelements primarily via histone deacetylation,
H3K9 trimethylation, and HP1 recruitment, with DNA
methylation occurring only secondarily to ensure the
permanence of the silencing process [187, 188].
Evolutionary old L1 subfamilies that are between ~ 7
and 25 million years of age are silenced in hESCs [98,
185, 189] through specific KRAB-ZFPs such as ZNF93/
KAP1, and there is evidence suggesting that KRAB-ZFPs
also bind the younger and retrotransposition-competent
L1Hs elements [185]. Beside L1s, in hESCs two-thirds of
endogenous retroelements bound by KAP1 are SVAs,
suggesting KAP1 is a major repressor of SVA activity. In
summary, it is now well established that KRAB-ZFP/
KAP1 complexes control TE activity in hESCs, including
retrotransposition-competent elements harbouring the
potential to affect genomic integrity, and help maintain-
ing transcriptional homeostasis and normal differenti-
ation of ESCs.
DNA-Methylation at CpG dinucleotides plays a piv-
otal role in TE silencing in both somatic and germ cells,
and has been suggested to have evolved primarily to pro-
tect the host against TEs. [93, 190, 191]. In mammals,
CpG methylation is established by DNA methyltransfer-
ases DNMT3a, 3b, 3L and 3C and maintained by DNA
methyltransferase DNMT1 and cofactors. DNMTs are
required to reestablish TE DNA methylation after the
two waves of reprogramming undergone by germ cells
and early embryos [192–195]. DNA-methylation is
known to control L1 expression, and the L1 promoter
has a canonical CpG island whose methylation is in-
versely correlated with L1 expression [93, 148, 149, 196].
As early embryonic models, hESCs/hiPSCs show sig-
nificant hypomethylation of L1 promoters, overexpress
full-length L1 mRNA, L1 ORF1p and L1-RNPs [79, 96–
101, 132, 133, 197, 198]. However, DNA methylation is
also involved in the long-term transcriptional control of
currently inactive L1 s, and in hESCs, L1PA4 and L1PA5
exhibit higher methylation levels than the currently ac-
tive L1Hs elements [98]. Investigation of the correlation
between CpG methylation and TE expression in naïve
and primed human ESCs uncovered that TEs in naïve
cells were hypomethylated relative to primed cells [128].
Despite the overall low methylation in naïve hESCs, en-
dogenous SVAs, which represent the most overexpressed
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TE family in these cells, tended to be more hypomethy-
lated compared to non-overexpressed copies in naïve cells
[128]. Thus, DNA methylation is key to control L1 expres-
sion and mobilization, and is the major TE controlling
mechanism during gastrulation [125].
TET proteins: While the primary mechanism under-
lying DNA demethylation during the early embryonic
period is replication-coupled dilution of 5mC [199,
200], an active mechanism dependent on TET enzymes
has recently been uncovered to erase DNA methylation
at specific loci in this period [170, 201–203]. TET en-
zymes catalyze the oxidation of 5-methylcytosine to
5-hydroxymethylcytosine (5hmC), and further to 5-for-
mylcytosine (5fC) and 5-carboxylcytosine (5caC), which
can be replaced with unmodified cytosine by base excision
repair [204, 205]. Some of the TET proteins are highly
expressed in ESCs and blastocysts [206], and it was re-
ported that TET binding and demethylation at particular
TE classes, such as LTR retrotransposons, acts in concert
with pluripotency factors Nanog, Oct4 and Sox2 to main-
tain expression of a subset of genes in ESCs [170]. Deple-
tion of TET1 and TET2 in mESCs has been shown to
cause loss of 5hmC in the 5′ region of L1 [207]. In hESCs,
TET proteins were shown to preferentially bind to evolu-
tionary young, functional L1 elements, and participate in
their active demethylation, but do not interact with older,
inactive subfamilies. Although TETs drive L1 demethyla-
tion, L1s can be kept repressed through the
TET-dependent recruitment of the transcriptional repres-
sor SIN3A. The SIN3A co-repressive complex binds func-
tional L1s in mouse and human ESCs ensuring their
repression in a TET-dependent manner [92, 170]. Thus,
and instead of being only positive regulators of L1 expres-
sion, TET enzymes may have a dual role in TE regulation
by also recruiting SIN3A to demethylated L1 elements. A
recent report provided evidence that the methyl-CpG
binding domain as well as the adjacent non-sequence spe-
cific DNA binding domain of MeCP2 mediate repression
of TET1-induced L1 mobilization [208]. Also, the KZFP/
KAP1 complex was recently reported to maintain hetero-
chromatin and DNA methylation at TEs in naïve murine
ESCs partly by protecting these loci from TET-mediated
demethylation [209].
Small RNAs classes include PIWI-interacting RNAs
(piRNAs), endogenously produced small interfering RNAs
(siRNAs) or micro RNAs (miRNAs), and the importance
of small RNA-based repression in the control of L1 ex-
pression in human pluripotent stem cells has been re-
ported and reviewed [114, 210, 211]. Double-stranded
RNAs (dsRNAs) with sequence specificity to portions of
the transcriptome that originate from TEs with bidirec-
tional promoters, such as L1s, was suggested to serve as
substrate for the production of siRNAs [212]. Moreover,
dsRNA produced from the 5’UTR of L1 may trigger the
interferon-dependent restriction factor ribonuclease L in
some cancer cells, leading to L1 mRNA degradation [213].
piRNAs are a complex class of small non-coding RNAs
that comprise mostly 24–32 nucleotides, specifically inter-
act with the PIWI protein subfamily of the ARGONAUTE
family [214], and act to repress mobile genetic elements in
the germline of Drosophila and mammals [169]. piRNAs
are generated by transcription of long TE clusters, result-
ing in the accumulation of short mature piRNAs in the
cytoplasm by the ping-pong mechanism [215]. piRNAs
then act as guides to destroy complementary TE tran-
scripts by endonucleolytic cleavage. PIWI-mediated con-
trol is indeed triggered by the recognition of L1-proximal
sequences by a complex encompassing a member of the
PIWI subclade of Argonaute proteins and L1-derived piR-
NAs, which leads to L1 transcriptional inhibition via DNA
methylation [216–218]. The piRNAs–PIWI system and
DNA methyltransferases, acting downstream of piRNA
action, play a crucial role in the early embryonic control
of the youngest and mobile L1 lineages in human pluripo-
tent cells [98, 186, 211, 219].
A role for miRNAs and the miRNA biogenesis ma-
chinery in controlling human non-LTR retrotransposons
has been suggested by demonstrating that a complex
termed Microprocessor, which comprises the RNase III
type enzyme Drosha and its partner DGCR8, catalyzes
the nuclear step of microRNA biogenesis [220, 221] and
binds L1, Alu and SVA-derived small RNAs in human
cells [210]. The results suggest that Microprocessor rec-
ognizes and processes structural regions within
retrotransposition-competent L1 and Alu elements lead-
ing to a decrease of functional L1 and Alu RNAs which
could result in a reduction of L1 and Alu retrotransposi-
tion frequencies [169, 210]. miR-128, a member of the
class of miRNAs encompassing 20- to 24-nt-long non-
coding RNAs that inhibit translational initiation and
stimulate decay of mRNA targets [222, 223], was re-
cently reported to decrease both amounts of full-length
L1 RNA and engineered L1 retrotransposition frequen-
cies in a cell culture based assay in human tumor cells
and induced pluripotent stem cells [198].
Post-transcriptional control of TEs
APOBEC3 proteins The human APOBEC3 (Apolipo-
protein B mRNA Editing Enzyme Catalytic Polypeptide
3, A3) protein family of cytidine deaminases comprises
seven members (APOBEC3A [A3A], APOBEC3B [A3B],
APOBEC3C [A3C], APOBEC3DE [A3DE], APOBEC3F
[A3F], APOBEC3G [A3G], APOBEC3H [A3H]) [224–
227], that inhibit the human non-LTR retrotransposons
L1 and Alu with varying degrees of efficiency [reviewed
in [228–230]. While A3B, A3C, A3DE, A3F and A3G
were shown to be expressed in hESCs, A3A is absent
from hESCs [105], but transiently overexpressed by up
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to 10-fold during reprogramming [132]. A3B is a nuclear
protein that is also expressed in hiPSCs [105, 231, 232] and
was demonstrated to restrict L1 retrotransposition in both
hESCs [105] and hiPSCs in a deaminase-independent man-
ner [211]. While it is likely that A3A inhibits L1 retrotran-
sposition by deaminating transiently exposed L1 DNA
[233], both A3C and A3DE were reported to restrict L1
retrotransposition through editing-independent mecha-
nisms by interacting with ORF1p, thereby interfering with
L1 RT activity [234, 235]. Additional mechanistic studies
are required, because contradictory results were found
among cell lines and studies.
SAMHD1, a dGTP-activated deoxynucleoside triphos-
phate triphosphohydrolase that inhibits L1 retrotranspo-
sition in actively dividing cells by reducing the L1
ORF2p level [236], was demonstrated to be transiently
induced during the initial 10 days of reprogramming
[132], and could therefore play a role in the restriction
of L1 mobilization during this period. In addition to
diminishing L1 reverse transcription by reducing L1
ORF2p expression [236], SAMHD1 was recently re-
ported to stimulate the formation of stress granules and
thus enhance the sequestration of L1 RNP complexes in
these granules [237].
TEX19.1 is expressed in germ cells, pluripotent cells
and the placenta of mammals [238] and was recently
shown to regulate L1-ORF1p levels and mobilization of
engineered L1 elements in pluripotent mouse embryonic
stem cells [106]. Mouse TEX19.1, and its human
ortholog TEX19, physically interact with L1-ORF1p, and
can regulate L1-ORF1p abundance at postranslational
level through stimulating its polyubiquitylation and
proteasome-dependent degradation [106].
For the sake of completeness, we also mention the fol-
lowing host-encoded factors which also restrict L1 retro-
transpositrion mostly by post-transcriptional mechanisms,
but have not been reported to restrict L1 mobilization in
stem cells so far: (i) MOV10, an RNA helicase that medi-
ates access of the RNA-induced silencing complex to mes-
senger RNAs [239, 240] (ii) ZAP, an antiviral member of
the poly (ADP-ribose) polymerase (PARP) protein family
[241, 242] (iii) TREX-1, a three-prime DNA exonuclease
[243, 244].
DNA transposons as tools for genetic engineering of
stem cells
An important point of intersection between stem cells
and transposable elements is genetic engineering for the
purposes of deciphering disease mechanisms and for
gene- and cell-based therapeutics. DNA (Class 2) trans-
posons (Fig. 4a) became major tools for genome manip-
ulations in a wide range of cell types, including stem
cells (reviewed by [245–247]. The mobility of DNA
transposons invariably depends on two functional com-
ponents: a protein component called the transposase
and a DNA component called inverted terminal repeats
(ITRs) supporting binding of and cleavage by the trans-




Fig. 4 Use of class II transposons as gene vectors. a Autonomous DNA transposons consist of a transposase-coding gene that is flanked by
inverted terminal repeats (ITR; black arrows flanked by white arrows). b Bi-component transposon vector system for delivering plasmid-encoded
transgenes. One component consists of a plasmid containing a gene of interest (GOI) flanked by transposon ITRs. The second component is a
transposase expression plasmid. Black arrow, promoter driving expression of transposase gene. c The transposon carrying a GOI is excised from
the donor plasmid and integrated at a chromosomal site by the transposase
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efficient gene transfer in human cell types, ease of ex-
perimental manipulation, and detailed understanding of
the transposition process, the Sleeping Beauty, piggyBac
and Tol2 transposons have become the transposons of
choice for stem cell engineering. What is common to all
gene transfer applications by any transposon is the setup
of a conditional, two-component gene delivery system,
in which a gene of interest flanked by the transposon ITRs
is mobilized out of standard plasmid vectors by the trans-
posase that is conditionally and transiently expressed in
the relevant cells (Fig. 4b and c). Stem cells are ideal tar-
gets for gene therapy applications. It is of great hope to
consider stem cells to achieve tissue repair or to restore
and replenish cells in the background of a genetic disease.
Following a transposon-based genetic manipulation step
to introduce a gene of interest, such as a therapeutic gene
rendering stable phenotypic correction, stem cells can be
expanded in vitro and then subjected to differentiation
into particular cell lineages according to the specific thera-
peutic need. There is now widespread evidence for robust
transposon-mediated gene transfer in several, clinically
relevant stem cell types, such as ESCs, iPSCs, CD34+
hematopoietic stem cells (HSC), MSCs, or myoblasts.
Transgene expression in hESCs by means of the Sleeping
Beauty transposon system
A proof of concept study established efficient and stable
transgene expression in hESCs using the Sleeping Beauty
transposon system. In this study, transposons, carrying
different transgenes coding for genetic markers, were ef-
fectively delivered to undifferentiated hESCs. The source
of transposase was either DNA or mRNA. Molecular
analysis indicated that 98% of stable gene transfer re-
sulted from transposition events. These genetically engi-
neered hESCs were then differentiated into teratomas in
vivo and mature hematopoietic cells in vitro and the
progeny maintained stable transgene expression [248].
Similarly successful gene transfer in hESCs was obtained
with the piggyBac system as well, where fluorescent re-
porters were introduced into ESCs, and these remained
functional following in vitro differentiaton. The piggyBac
transposon system also allowed for seamless restoration
of the insertion site following transposon removal by a
second round of transient transposase expression [249].
The Sleeping Beauty transposon was also used to intro-
duce a CAG promoter-driven GFP expression cassette
to hESCs. During differentiation experiments the CAG
promoter yielded outstanding GFP expression in cardio-
myocytes allowing for specific labeling of cardiomyo-
cytes in a spontaneously differentiated, mixed cell
population [250]. The same transposon was also used to
introduce a genetically encoded Ca2+ions indicator
(GCaMP2) into hESCs allowing for real-time Ca imaging
without the need for dyes. Cardiomyocytes differentiated
from these ESCs were characterized by their spontaneous
contractions and Ca2+ signal oscillations, presenting a
powerful tool for pharmacological screening assays [251].
Multiple applications of transposon systems in the hiPSC
field
During the early developments in the iPSC field, a signifi-
cant step was achieved when non-viral methods were used
to achieve reprogramming. Both piggyBac [252] and Sleep-
ing Beauty [253, 254] were successfully used to generate
hiPSCs, and transposons remained relevant gene transfer
tools in the context of hiPSCs generated from
patient-derived cells with a disease-causing genetic back-
ground. In this scenario transposons can be effectively used
to correct a disease phenotype by introducing functional
genes into hiPSCs followed by differentiating the relevant
cell types that can be used for therapeutic purposes. In a
preclinical mouse model of Duchenne muscular dystrophy,
hiPSCs were corrected with the Sleeping Beauty trans-
poson system carrying the micro-utrophin gene. Cells were
then differentiated into skeletal muscle progenitors.
Following transplantation of these progenitors into dys-
trophic mice, engrafted muscles displayed large numbers
of micro-utrophin-positive myofibers, with biochemically
restored dystrophin-glycoprotein complex and improved
contractile strength [255]. Transposon-based gene delivery
is not only useful for correcting a genetic disease, but can
also be applied to coax differentiation into a particular cell
lineage. For example, drug-inducible expression of
MYOD1 from a piggyBac transposon vector in hiPSCs for
at least 5 days was demonstrated to lead to highly efficient
differentiation into myocytes [256]. In a similar experi-
ment, Sleeping Beauty-mediated overexpression of PAX3
in iPSCs induced differentiation into MYOD positive myo-
genic progenitors and multinucleated myofibers [257].
Transposons can also be used in combination with de-
signer nucleases in iPSCs to correct gene defects. For ex-
ample, the efficiency of endonuclease-based gene targeting
can be enhanced by using the piggyBac transposon as an
efficient, transient drug selection tool due to the possibility
of seamless removal of the drug marker enabled by the
re-transfection of the transposase [258]. In ß-thalassemia
patient-derived iPSCs, piggyBac transposon-mediated pur-
oΔtk-based drug selection was used in combination with
CRISPR/Cas9 to achieve correction of the mutation in the
Hemoglobin Beta Chain (HBB) gene [259]. A similar strat-
egy was used in combination with CRISPR/Cas9 in
Huntington disease iPSCs to correct mutations in the
Huntigtin (HTT) gene. The corrected cells were then suc-
cessfully differentiated into excitable, synaptically active
forebrain neurons [260]. A different combination of
CRISPR/Cas9 and piggyBac transposon demonstrated the
versatility of combinations with different genome editing
tools in iPSCs. The Cas9 gene driven by an inducible
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promoter was delivered by the transposon, and genomic
modification was achieved following sgRNA delivery. Fol-
lowing a transient transposase expression the inducible
Cas9 cassette was removed yielding a genome-edited iPSC
clone with seamless transgene removal [261].
Efficient gene transfer into mobilized HSCs and human
CD34+ cord blood cells
A rapidly progressing area for transposon-mediated gene
therapy applications is represented by HSCs.
Transposon-based tools hold great promise for render-
ing efficient gene correction without the potential risks
inherent to viral delivery methods, which resulted in se-
vere adverse reactions in clinical trials in the past [262,
263]. HSCs have the potential for self-renewal and main-
tenance of the ability to differentiate into hematopoietic
lineages, and are thus ideal targets for gene therapy ap-
plications in hematologic diseases. HSCs can be effi-
ciently modified by the Sleeping Beauty and piggyBac
transposon systems [264]. Especially, developments of
Sleeping Beauty transposons were taking shape in recent
years enabled by the highly efficient SB100X hyperactive
transposase in CD34+ HSCs [265]. The Sleeping Beauty
transposon system not only supports the efficient gene
transfer into mobilized CD34+ HSCs, but also into hu-
man cord blood CD34+ cells as shown in a model of
sickle cell disease [266]. Further developments of the
transposon-mediated delivery were also undertaken in
recent years to target CD34+ HSCs. For example, an in-
teresting and promising optimization step was under-
taken when the transposon was delivered to the cells as
a minicircle in combination with transposase supplied as
mRNA. This approach led to improved cell survival and
reduced cytotoxicity in the HSCs providing also several
biosafety advantages over conventional delivery methods
[267]. The combination of the Sleeping Beauty trans-
poson system and adenoviral vectors in a hybrid vector
system was also proposed as a promising method to
achieve in vivo gene delivery. This approach holds
broader clinical application potential for gene therapy as
it may circumvent the need for myeloablation and trans-
plantation. In this study HSCs were mobilized into per-
ipheral blood in a transgenic, humanized mouse model,
and were targeted using a hybrid adenovirus/transposon
vector system injected intravenously in vivo, resulting in
functional HSCs homing back to the bone marrow stably
expressing the transgene [268].
MSCs are also in the focus of regenerative medicine,
however, there are no breakthrough applications yet, and
the field is still hampered by many controversies. Never-
theless, it has been evidenced that both Sleeping Beauty
and piggyBac transposon-based gene transfer is applicable
in MSCs as well. The genetically engineered MSCs are still
characterized by the ability to undergo osteogenic,
myogenic, and adipogenic differentiation after modifica-
tions with the transposons [257, 269]. piggyBac-mediated
gene transfer of IFNγ into adipose-derived MSCs was
used in a mouse model of melanoma to show that the
IFNγ-expressing MSCs engrafted into tumor stroma,
inhibited tumor growth and angiogenesis, and prolonged
the survival of mice [270].
Myoblasts are self-renewing adult muscle progenitor
cells, which differentiate into skeletal muscle cells and
could potentially be harnessed for cell therapy of muscle
disorders. Both Sleeping Beauty- and piggyBac-mediated
gene transfer methods can be applied to efficiently modify
myoblasts and were shown to be useful tools in delivering
therapeutic genes into myoblasts. Proper dysferlin expres-
sion as well as highly efficient engraftment of the engi-
neered myoblasts was evidenced in the skeletal muscle of
dysferlin-deficient mice [271], whereas transposon vectors
encoding microdystrophins and delivered into myoblasts
have been shown to yield proper expression levels in dif-
ferentiated multinucleated myotubes [272].
Insertional mutagenesis and genetic labeling studies
DNA transposons have also been successfully used in
stem cells to identify different mechanisms of stemness
and differentiation in insertional mutagenesis and genetic
labeling studies. For such applications, the transposon vec-
tors are equipped with mutagenic and reporting features
(e. g., gene traps) that allow conditional expression of a
marker upon integration into a gene (reviewed in [246].
For example, a modified Sleeping Beauty transposon was
generated to randomly trap genes in the neural stem cell
genome and modify their expression or tag them with
fluorescent markers and selectable genes, allowing recom-
binant cells to be isolated and expanded clonally. This ap-
proach may facilitate the identification of novel
determinants of stem cell biology and neural cell fate spe-
cification in NSCs [273]. A modified Tol2 transposon was
also designed to allow for conditional disruption of a
broad spectrum of genes. The system was used in mouse
ESCs, and relied on differentially tagged Tol2 transposons
to discern individual integrations within a single cell [274].
A piggyBac transposon-based insertional mutagenesis
method has been developed to efficiently generate
genome-wide mutant libraries in mouse haploid ESCs
[275]. In hESCs a piggyBac insertional mutagenesis screen
was used to identify the role of nuclear RhoA during stem
cell differentiation [276]. The Sleeping Beauty transposon
has been also used to explore the clonal dynamics of na-
tive haematopoiesis in vivo allowing for a specific fate
tracking approach based on in situ labelling of HSCs.
DsRed-positive HSCs harboring distinct insertion sites re-
sulted from inducible transposition events fully reconsti-
tuted myeloid and lymphoid lineages evidencing
successful tagging. These experiments established that
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steady-state blood production is maintained by the succes-
sive recruitment of thousands of clones, each with a min-
imal contribution to mature progeny. These results
demonstrated that large numbers of long-lived progeni-
tors are the main drivers of steady-state haematopoiesis
during most of adulthood [277].
The risk of genotoxicity caused by DNA transposon activity
As discussed above in the context of endogenous TEs, one
of the most important risk factors also associated with the
use of transposon-based gene transfer tools in stem cells is
genotoxicity. In the context of a transposon vector system,
at least two fundamental properties can contribute to gen-
otoxicity: i) interaction of the transposase with endogenous
human DNA sequences or human proteins with the trans-
poson vector sequences and ii) the genome-wide insertion
profile of the vector. With respect to “off-target” cleavage
of the transposase, the use of the Sleeping Beauty and Tol2
systems appears to be safe in human cells. Both of these
transposons originate from fish genomes, and the mamma-
lian lineage does not contain transposons sufficiently simi-
lar to allow cleavage by these transposases. Vice versa,
human cells do not express proteins that could re-mobilize
a genomically integrated Sleeping Beauty or Tol2 vector. In
contrast, the human PGBD5 transposase-derived protein
was reported to mobilize piggyBac transposon vectors in
human cells [278], thereby presenting potential implica-
tions for human applications [279].
Characterization of the target site selection properties
of different vector systems is highly useful for ranking
the different vector types and designs according to their
genotoxic potential [280]. The Sleeping Beauty trans-
poson displays the least deviation from random with re-
spect to genome-wide distribution: no apparent bias was
seen for either heterochromatin marks or euchromatin
marks and only a weak correlation with transcriptional
status of targeted genes was detected [281]. This is in
marked contrast to target site distributions of several
other transposons including Tol2 [264, 282], and piggy-
Bac [264, 283, 284] that favor integration into genes and
near chromatin marks characteristic of active transcrip-
tion units (e.g., H3K27 acetylation and H3K4 mono-
methylation). The piggyBac transposon, in particular, has
been shown to favor open chromatin, expressed genes
and TSSs (±5 kb) associated with DNaseI hypersensitive
sites, H3K4Me3 marks and Pol II-bound regions in
mouse and human cells [283–288]. These observations
collectively suggest that Sleeping Beauty might be the
safest currently available transposon for therapeutic gene
delivery in clinical trials.
Conclusions
Stem cell therapies have been expected to bring substantial
benefit to patients suffering a wide range of diseases and
injuries. It was expected that the benefits of bone marrow
transplants for patients needing reconstruction of their
hematopoietic and immune system would apply to stem
cell transplants of other cell types, and optimism has been
high for the utilization of embryonic and induced pluripo-
tent stem cells for a variety of applications. However, be-
fore these promising stem cells or their differentiated
derivatives are administered to patients, genomic integrity
of these cells has to be ensured to guarantee that these
cells remain therapeutically functional and are not tumori-
genic. In recent years, a remarkable amount of data accu-
mulated showing that the activity of endogenous TEs can
be one source of genomic destabilization in stem cells, and
constitutes a risk for the biosafety of stem cell-based ther-
apies. By giving an overview of the potentially mutagenic
activity of TEs in human multipotent and pluripotent stem
cells, the consequences of their activity for the genomic in-
tegrity and host gene expression, we provide arguments for
a thorough characterization of TE activity and its conse-
quences in the individual stem cell lines before their thera-
peutic utilization in patients in order to ensure biosafety of
these stem cells cells and/or their applied derivatives.
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